Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation01:21

Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation

Clinical manifestationsPeripheral Arterial Disease (PAD) manifests through a range of symptoms, from the characteristic intermittent claudication to atypical presentations and severe complications in advanced stages. Intermittent claudication, a hallmark symptom of PAD, presents as exercise-induced muscle pain that typically resolves within minutes of rest. This pain is reproducible and stems from inadequate blood flow, leading to the accumulation of lactic acid produced during anaerobic...
Phosphoinositides and PIPs01:42

Phosphoinositides and PIPs

Phosphoinositides are a group of phospholipids containing a glycerol backbone with two fatty acid chains and a phosphate attached to a myoinositol sugar ring. The inositol head group extends into the cytoplasm, where it is modified by adding phosphate groups to form phosphatidylinositol phosphates or PIPs.
Different phosphoinositides are synthesized and recruited on the cytosolic face of the plasma membrane. The localization of specific phosphoinositides concentrated in separate membrane...
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies01:20

Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies

The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests01:27

Atherosclerosis II: Clinical Manifestations and Diagnostic Tests

Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Quest for Outpatient Mastectomy in COVID-19 Era: Barriers and Facilitators.

The breast journal·2022
Same author

2-year outcomes of phased radiofrequency ablation for atrial fibrillation with the second-generation PVAC Gold ablation catheter.

Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing·2022
Same author

Acute success and safety of the second-generation PVAC GOLD phased RF ablation catheter for atrial fibrillation.

Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing·2020
Same author

Factors associated with first thrombosis in patients presenting with obstetric antiphospholipid syndrome (APS) in the APS Alliance for Clinical Trials and International Networking Clinical Database and Repository: a retrospective study.

BJOG : an international journal of obstetrics and gynaecology·2018
Same author

Longitudinal evaluation of diffusion tensor imaging and cognition in systemic lupus erythematosus.

Lupus·2018
Same author

McMaster RARE-Bestpractices clinical practice guideline on diagnosis and management of the catastrophic antiphospholipid syndrome.

Journal of thrombosis and haemostasis : JTH·2018
Same journal

Association of systemic lupus erythematosus with 90-day readmission following heart failure hospitalization: A national readmission database (NRD) analysis, 2016-2017.

Lupus·2026
Same journal

Association of GPX4 rs713041 and rs4807542 polymorphisms and serum GPX4 levels in Chinese patients with systemic lupus erythematosus.

Lupus·2026
Same journal

Giant cell myocarditis in an 18-year-old patient with new-onset systemic lupus erythematosus: A fatal case of rapidly progressing heart failure.

Lupus·2026
Same journal

An evidence-based specialist nursing protocol for children with hypoprothrombinemia-lupus anticoagulant syndrome (HLAS) and its application research.

Lupus·2026
Same journal

T-bet expression in B cell subsets: Association with T peripheral helper cells and clinical activity in systemic lupus erythematosus.

Lupus·2026
Same journal

Autonomic dysfunction in systemic lupus erythematosus and systemic sclerosis.

Lupus·2026
See all related articles

Related Experiment Video

Updated: Jun 4, 2026

Procoagulant Platelet Characterization by Measuring Phosphatidylserine Exposure and Microvesicle Release from Human Purified Platelets
05:49

Procoagulant Platelet Characterization by Measuring Phosphatidylserine Exposure and Microvesicle Release from Human Purified Platelets

Published on: November 29, 2024

Antiphospholipid Syndrome Clinical Research Task Force report.

D Erkan1, R Derksen, R Levy

  • 1Hospital for Special Surgery, Weill Medical College of Cornell University, New York, NY, USA. erkand@hss.edu

Lupus
|February 10, 2011
PubMed
Summary
This summary is machine-generated.

Antiphospholipid Syndrome (APS) clinical research faces challenges due to non-standardized tests and heterogeneous patient groups. Improved international collaboration is crucial for well-designed APS clinical trials.

More Related Videos

A Fibrin-Enriched and tPA-Sensitive Photothrombotic Stroke Model
09:42

A Fibrin-Enriched and tPA-Sensitive Photothrombotic Stroke Model

Published on: June 4, 2021

Related Experiment Videos

Last Updated: Jun 4, 2026

Procoagulant Platelet Characterization by Measuring Phosphatidylserine Exposure and Microvesicle Release from Human Purified Platelets
05:49

Procoagulant Platelet Characterization by Measuring Phosphatidylserine Exposure and Microvesicle Release from Human Purified Platelets

Published on: November 29, 2024

A Fibrin-Enriched and tPA-Sensitive Photothrombotic Stroke Model
09:42

A Fibrin-Enriched and tPA-Sensitive Photothrombotic Stroke Model

Published on: June 4, 2021

Area of Science:

  • Rheumatology
  • Clinical Immunology
  • Thrombosis Research

Background:

  • Antiphospholipid Syndrome (APS) clinical research is hindered by several critical limitations.
  • Existing studies often use non-standardized tests and include heterogeneous patient populations, complicating evidence-based recommendations.

Purpose of the Study:

  • To evaluate limitations in Antiphospholipid Syndrome (APS) clinical research and propose guidelines for improvement.
  • To prioritize ideas for well-designed multicenter clinical trials and discuss their practical implementation.

Main Methods:

  • A systematic working algorithm was employed by the Antiphospholipid Syndrome (APS) Clinical Research Task Force (CRTF).
  • The task force identified five major issues impeding APS research and the development of clinical management guidelines.

Main Results:

  • Key issues identified include non-standardized aPL detection, heterogeneous patient cohorts, lack of risk stratification, inclusion of low-titer/single positive aPL results, and limited understanding of pathogenic mechanisms.
  • These factors collectively limit the quality and generalizability of current APS research.

Conclusions:

  • There is an urgent need for international collaboration to design and conduct large-scale, prospective, multicenter clinical trials.
  • Future research should focus on patients with persistent and clinically significant antiphospholipid antibody (aPL) profiles, utilizing standardized methodologies and robust study designs.